Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation

多种人类癌症中FAT1基因的反复体细胞突变导致Wnt信号通路异常激活。

阅读:2
作者:Luc G T Morris,Andrew M Kaufman, Yongxing Gong, Deepa Ramaswami, Logan A Walsh, Şevin Turcan, Stephanie Eng, Kasthuri Kannan, Yilong Zou, Luke Peng, Victoria E Banuchi, Phillip Paty, Zhaoshi Zeng, Efsevia Vakiani, David Solit, Bhuvanesh Singh, Ian Ganly, Linda Liau, Timothy C Cloughesy, Paul S Mischel, Ingo K Mellinghoff, Timothy A Chan

Abstract

Aberrant Wnt signaling can drive cancer development. In many cancer types, the genetic basis of Wnt pathway activation remains incompletely understood. Here, we report recurrent somatic mutations of the Drosophila melanogaster tumor suppressor-related gene FAT1 in glioblastoma (20.5%), colorectal cancer (7.7%), and head and neck cancer (6.7%). FAT1 encodes a cadherin-like protein, which we found is able to potently suppress cancer cell growth in vitro and in vivo by binding β-catenin and antagonizing its nuclear localization. Inactivation of FAT1 via mutation therefore promotes Wnt signaling and tumorigenesis and affects patient survival. Taken together, these data strongly point to FAT1 as a tumor suppressor gene driving loss of chromosome 4q35, a prevalent region of deletion in cancer. Loss of FAT1 function is a frequent event during oncogenesis. These findings address two outstanding issues in cancer biology: the basis of Wnt activation in non-colorectal tumors and the identity of a 4q35 tumor suppressor.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。